Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
This study will monitor developmental progress of PPHN patients for 2 years following study treatment, using Bayley III and Hammersmith tools. Data will be explored with descriptive statistics.
Age
0–1
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Any subject who received sildenafil treatment in study A1481276.
Signed and dated informed consent document by legal guardian.
You may not be if
Any subject who did not receive sildenafil treatment during study A1481276.
